GNTA

GNTA

Genenta Science SpA ADR

Net —top 1%Rev —top 1%1Y
Hold

Genenta Science S.p.A. develops hematopoietic stem cell gene therapies for solid tumors, focusing on glioblastoma multiforme and other indications. Its lead candidate, Temferon, is in clinical trials, aiming to deliver immunomodulatory therapies directly to tumors.

⚕️ Healthcare NASDAQ Listed 2021 € EUR
$1,000 invested 1 year ago $395today

Score Overview

1 Year
Score
Net Growth
Net Trend
Net Income Consistency
Rev Growth
Rev Trend
Revenue Consistency
All Time
Score
Net Growth
Net Trend50%
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency

See the full market ranking →

Genenta Science SpA ADR fundamental performance

Across Genenta Science SpA ADR's full reported history, from 2021 to 2025, revenue held from € 0.00 to € 0.00 and net income went from -€ 5M to -€ 6M. Revenue increased in 0% of the years measured; net income in 50%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.30
1 Year2025-08-12
$ 3.29-60.49%
All Time2021-12-15
$ 11.00-88.18%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026€ 28M
2025€ 0.00-€ 6M€ 28M
2024€ 0.00-€ 9M€ 12M
2023€ 0.00-€ 11M€ 18M
2022€ 0.00-€ 8M€ 29M
IPO2021€ 0.00-€ 5M€ 37M

Explore beyond GNTA

You're looking at Genenta Science SpA ADR. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies